Dublin, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Bipolar Disorder: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.
Generic dominance will prevent the growth of the bipolar disorder market, and few pipeline candidates show promise to completely reverse this trend.
This report addresses the following questions:
- What are the key events shaping the bipolar disorder market dynamics over 2014-23?
- Which segments of the market provide opportunities for growth?
- How does the bipolar disorder pipeline compare to other psychiatric indications, and what are the candidates to look out for?
- How do currently available bipolar disorder drugs compare to one another?
- What is the standard of care in bipolar disorder, and which are the key unmet needs in treatment?
Key Topics Covered:
FORECAST: BIPOLAR DISORDER
- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Abilify (aripiprazole)
- Abilify Maintena (aripiprazole)
- Latuda (lurasidone)
- Risperdal Consta (risperidone)
- Saphris (asenapine)
- Seroquel/Seroquel XR (quetiapine fumarate)
- Vraylar (cariprazine)
- Primary Research Methodology
TREATMENT: BIPOLAR DISORDER
- Executive Summary
- Primary Research Methodology,
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in Bipolar Disorder
EPIDEMIOLOGY: BIPOLAR DISORDER IN THE US, JAPAN, AND 5EU
- Executive Summary
- Disease Definition
- Global Variation
- Risk Factors
- Co-Morbidities
- Sources and Methodology
- Forecast
- Forecast: Bipolar Disorder I
- Forecast: Bipolar Disorder II
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography
MARKETED DRUGS: BIPOLAR DISORDER
- Executive Summary
- Product Overview
- Other Marketed Drugs
- Product profile: Abilify
- Product profile: Geodon
- Product profile: Lamictal
- Product profile: Latuda
- Product profile: Risperdal/Risperdal Consta
- Product profile: Saphris
- Product profile: Seroquel/Seroquel XR
- Product profile: Vraylar
- Product profile: Zyprexa
PIPELINE: BIPOLAR DISORDER
- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Clinical Trial Design
- The Future of Treatment
- Recently Discontinued Drugs
- Product profile (late stage): ITI-007
For more information about this report visit http://www.researchandmarkets.com/research/d2fd69/bipolar_disorder
Bipolar Disorder: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis 2014-2023
| Source: Research and Markets